Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc

L. C. Boffa, G. Cutrona, M. Cilli, S. Matis, G. Damonte, M. R. Mariani, E. Millo, M. Moroni, S. Roncella, F. Fedeli, M. Ferrarini

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

In Burkitt's lymphoma (BL) cells due to a t(8;14) chromosomal translocation c-myc is often placed in proximity to the Eμ enhancer of the Ig locus and upregulated. We demonstrated that in BL cells a peptide nucleic acid (PNA), complementary to intronic Eμ sequences (PNAEμwt), specifically blocks the expression of the c-myc oncogene under the Eμ enhancer control and inhibits BL cell growth in culture. Here, we investigated whether PNAEμwt was also able to block tumor growth in SCID mice inoculated with human BL cell lines. After subcutaneous inoculum in mice BL cells reproducibly form tumors. Both pre-treatment of BL cells with PNAEμwt before inoculum and chronic intravenous administration of PNAEμwt to mice already inoculated with BL cells selectively caused increased latency of tumor appearance and decreased final tumor size. Tumors from PNAEμwt-treated animals showed substantial areas of cell necrosis and of c-myc downregulation. Inhibition of tumor growth was specific and was not observed with PNAEμmut carrying sequence mutations and in BL cell lines where the translocated c-myc is not under the control of the Eμ enhancer. These data confirm the potential therapeutic value of PNA targeted to regulatory non-coding regions.

Original languageEnglish
Pages (from-to)220-226
Number of pages7
JournalCancer Gene Therapy
Volume14
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Peptide Nucleic Acids
SCID Mice
Burkitt Lymphoma
Growth
Neoplasms
Cell Line
Genetic Translocation
myc Genes
Intravenous Administration
Necrosis
Down-Regulation
Mutation

Keywords

  • Burkitt's lymphoma
  • c-myc
  • Eμ enhancer
  • Gene downregulation
  • PNA

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc. / Boffa, L. C.; Cutrona, G.; Cilli, M.; Matis, S.; Damonte, G.; Mariani, M. R.; Millo, E.; Moroni, M.; Roncella, S.; Fedeli, F.; Ferrarini, M.

In: Cancer Gene Therapy, Vol. 14, No. 2, 02.2007, p. 220-226.

Research output: Contribution to journalArticle

Boffa, LC, Cutrona, G, Cilli, M, Matis, S, Damonte, G, Mariani, MR, Millo, E, Moroni, M, Roncella, S, Fedeli, F & Ferrarini, M 2007, 'Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc', Cancer Gene Therapy, vol. 14, no. 2, pp. 220-226. https://doi.org/10.1038/sj.cgt.7701002
Boffa, L. C. ; Cutrona, G. ; Cilli, M. ; Matis, S. ; Damonte, G. ; Mariani, M. R. ; Millo, E. ; Moroni, M. ; Roncella, S. ; Fedeli, F. ; Ferrarini, M. / Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc. In: Cancer Gene Therapy. 2007 ; Vol. 14, No. 2. pp. 220-226.
@article{5a96dd498777420fbbe1adf592f0633f,
title = "Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc",
abstract = "In Burkitt's lymphoma (BL) cells due to a t(8;14) chromosomal translocation c-myc is often placed in proximity to the Eμ enhancer of the Ig locus and upregulated. We demonstrated that in BL cells a peptide nucleic acid (PNA), complementary to intronic Eμ sequences (PNAEμwt), specifically blocks the expression of the c-myc oncogene under the Eμ enhancer control and inhibits BL cell growth in culture. Here, we investigated whether PNAEμwt was also able to block tumor growth in SCID mice inoculated with human BL cell lines. After subcutaneous inoculum in mice BL cells reproducibly form tumors. Both pre-treatment of BL cells with PNAEμwt before inoculum and chronic intravenous administration of PNAEμwt to mice already inoculated with BL cells selectively caused increased latency of tumor appearance and decreased final tumor size. Tumors from PNAEμwt-treated animals showed substantial areas of cell necrosis and of c-myc downregulation. Inhibition of tumor growth was specific and was not observed with PNAEμmut carrying sequence mutations and in BL cell lines where the translocated c-myc is not under the control of the Eμ enhancer. These data confirm the potential therapeutic value of PNA targeted to regulatory non-coding regions.",
keywords = "Burkitt's lymphoma, c-myc, Eμ enhancer, Gene downregulation, PNA",
author = "Boffa, {L. C.} and G. Cutrona and M. Cilli and S. Matis and G. Damonte and Mariani, {M. R.} and E. Millo and M. Moroni and S. Roncella and F. Fedeli and M. Ferrarini",
year = "2007",
month = "2",
doi = "10.1038/sj.cgt.7701002",
language = "English",
volume = "14",
pages = "220--226",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc

AU - Boffa, L. C.

AU - Cutrona, G.

AU - Cilli, M.

AU - Matis, S.

AU - Damonte, G.

AU - Mariani, M. R.

AU - Millo, E.

AU - Moroni, M.

AU - Roncella, S.

AU - Fedeli, F.

AU - Ferrarini, M.

PY - 2007/2

Y1 - 2007/2

N2 - In Burkitt's lymphoma (BL) cells due to a t(8;14) chromosomal translocation c-myc is often placed in proximity to the Eμ enhancer of the Ig locus and upregulated. We demonstrated that in BL cells a peptide nucleic acid (PNA), complementary to intronic Eμ sequences (PNAEμwt), specifically blocks the expression of the c-myc oncogene under the Eμ enhancer control and inhibits BL cell growth in culture. Here, we investigated whether PNAEμwt was also able to block tumor growth in SCID mice inoculated with human BL cell lines. After subcutaneous inoculum in mice BL cells reproducibly form tumors. Both pre-treatment of BL cells with PNAEμwt before inoculum and chronic intravenous administration of PNAEμwt to mice already inoculated with BL cells selectively caused increased latency of tumor appearance and decreased final tumor size. Tumors from PNAEμwt-treated animals showed substantial areas of cell necrosis and of c-myc downregulation. Inhibition of tumor growth was specific and was not observed with PNAEμmut carrying sequence mutations and in BL cell lines where the translocated c-myc is not under the control of the Eμ enhancer. These data confirm the potential therapeutic value of PNA targeted to regulatory non-coding regions.

AB - In Burkitt's lymphoma (BL) cells due to a t(8;14) chromosomal translocation c-myc is often placed in proximity to the Eμ enhancer of the Ig locus and upregulated. We demonstrated that in BL cells a peptide nucleic acid (PNA), complementary to intronic Eμ sequences (PNAEμwt), specifically blocks the expression of the c-myc oncogene under the Eμ enhancer control and inhibits BL cell growth in culture. Here, we investigated whether PNAEμwt was also able to block tumor growth in SCID mice inoculated with human BL cell lines. After subcutaneous inoculum in mice BL cells reproducibly form tumors. Both pre-treatment of BL cells with PNAEμwt before inoculum and chronic intravenous administration of PNAEμwt to mice already inoculated with BL cells selectively caused increased latency of tumor appearance and decreased final tumor size. Tumors from PNAEμwt-treated animals showed substantial areas of cell necrosis and of c-myc downregulation. Inhibition of tumor growth was specific and was not observed with PNAEμmut carrying sequence mutations and in BL cell lines where the translocated c-myc is not under the control of the Eμ enhancer. These data confirm the potential therapeutic value of PNA targeted to regulatory non-coding regions.

KW - Burkitt's lymphoma

KW - c-myc

KW - Eμ enhancer

KW - Gene downregulation

KW - PNA

UR - http://www.scopus.com/inward/record.url?scp=33846248757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846248757&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7701002

DO - 10.1038/sj.cgt.7701002

M3 - Article

C2 - 17053816

AN - SCOPUS:33846248757

VL - 14

SP - 220

EP - 226

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 2

ER -